Curative Financial Statements From 2010 to 2024

CBDX Stock  USD 0.0001  0.00  0.00%   
Curative Biosciences financial statements provide useful quarterly and yearly information to potential Curative Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Curative Biosciences financial statements helps investors assess Curative Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Curative Biosciences' valuation are summarized below:
Curative Biosciences does not presently have any fundamental signals for analysis.
Check Curative Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Curative Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Curative financial statements analysis is a perfect complement when working with Curative Biosciences Valuation or Volatility modules.
  
This module can also supplement various Curative Biosciences Technical models . Check out the analysis of Curative Biosciences Correlation against competitors.

Curative Biosciences Company Shares Owned By Insiders Analysis

Curative Biosciences' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

 = 

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current Curative Biosciences Shares Owned By Insiders

    
  76.24 %  
Most of Curative Biosciences' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Curative Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition

Based on the latest financial disclosure, 76% of Curative Biosciences are shares owned by insiders. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.

Curative Biosciences Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Curative Biosciences's current stock value. Our valuation model uses many indicators to compare Curative Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Curative Biosciences competition to find correlations between indicators driving Curative Biosciences's intrinsic value. More Info.
Curative Biosciences is number one stock in return on asset category among its peers. It also is the top company in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Curative Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Curative Biosciences' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Curative Biosciences Financial Statements

Curative Biosciences investors use historical fundamental indicators, such as Curative Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Curative Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. Curative Biosciences, Inc. was founded in 2009 and is based in Miami, Florida. Curative Biosciences is traded on OTC Exchange in the United States.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Curative Pink Sheet Analysis

When running Curative Biosciences' price analysis, check to measure Curative Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biosciences is operating at the current time. Most of Curative Biosciences' value examination focuses on studying past and present price action to predict the probability of Curative Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biosciences' price. Additionally, you may evaluate how the addition of Curative Biosciences to your portfolios can decrease your overall portfolio volatility.